Also trades as: BFRI (NASDAQ) · $vol 0M
BFRIW NASDAQ
Biofrontera Inc.
1W: -64.8%
1M: -40.6%
3M: -68.3%
YTD: -73.8%
1Y: -43.1%
$0.02
+0.00 (+0.00%)
Weekly Expected Move ±109.3%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.3M
52W Range0.0222-0.0971
Volume19,281
Avg Volume4,049
Beta3.39
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOHermann Luebbert
Employees92
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2021-10-29
Websitebiofrontera-us.com
120 Presidential Way
Woburn, DE 01801
US
Woburn, DE 01801
US
781-245-1325
About Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Luebbert Hermann | A-Award | 125,000 | — | 2026-03-04 |